.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX17_EnisamiumIodide.EnisamiumIodide .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX17_EnisamiumIodide.EnisamiumIodide| name: | EnisamiumIodide | |
| ATC code: | J05AX17 | |
| route: | oral | |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | L/h |
| other parameters in model implementation | ||
Enisamium iodide is an isonicotinic acid derivative used as an antiviral agent, primarily investigated for the treatment of influenza and, more recently, for COVID-19. It is commercialized in several countries in Eastern Europe and Asia as an over-the-counter medication, but it is not widely approved or used in Western countries.
No peer-reviewed pharmacokinetic studies reporting actual parameter values (bioavailability, clearance, volume of distribution, etc.) of enisamium iodide in humans have been published as of June 2024.